NCT02964988

uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)

Detailed description

68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR), which is a promising imaging biomarker of tumor aggressiveness. 68Ga-NOTA-AE105 PET/CT will be applied in patients with mCRPC during treatment with Radium-223. PET/CT will be performed before initiation of Radium therapy and after two treatment cycles. The initial semiquantitative uptake (standard uptake values, SUVs) of 68Ga-NOTA-AE105 in metastases as well as the change in these parameters after therapy will be correlated with overall survival and progression free survival.

Conditions

• Prostate Cancer Metastatic
• Bone Metastases

Interventions

Type	Name	Description
DRUG	Injection of PET tracer 68Ga-NOTA-AE105	Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
DEVICE	PET/CT	Whole body PET/CT

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-10-11
• Completion: 2019-10-11
• First posted: 2016-11-16
• Last updated: 2019-10-15

Locations

1 site across 1 country: Denmark